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With 37 million people around the world infected with HIV—and this number rising by almost 2 million a year—
the search for newer, better medicines to treat this deadly disease remains an important goal. MK-8591 is a 
nucleoside reverse transcriptase inhibitor currently undergoing clinical trials for the treatment of HIV. 
 
In order to achieve a world-class manufacturing route to this target that is also green and sustainable, the 
process chemistry team has turned to biocatalysis.  Specifically, the 4’-ethynyl-2’-deoxyribose sugar portion of 
the molecule is prepared via a highly efficient three-enzyme cascade sequence. Another multi-enzyme reaction 
system is then used to append the 2-fluoroadenine base, overcoming a challenging glycosylation reaction. 
 
This bold endeavor has posed numerous technical challenges in the optimization of complex multi-enzyme 
systems, the need for directed evolution of multiple enzymes, the detection and analysis of polar chromophore-
free molecules and the isolation of unstable and highly water-soluble intermediates. An overview of the ongoing 
development and unique challenges—and opportunities—of this unprecedented fully-enzymatic manufacturing 
route will be presented.  
 
 
 
 
